


## AIRP brings affordable biological products and services

21 December 2017 | News

**AIRP launched the first Biosimilar of Trastuzumab (CANMAb) in Algeria for the treatment of Her2+ breast cancer**



Abdi Ibrahim Remede Pharma (AIRP) is Biocon's partner in Algeria for the registration, marketing and pharmacovigilance monitoring of multiple Biotech Products.

Biocon Ltd., Asia's premier biopharmaceuticals company, obtained U.S. Food and Drug Administration (FDA) approval on 1st December 2017 for its biosimilar trastuzumab through its US Partner.

Biocon's trastuzumab has been approved in the US for all indications included in the label of the reference product including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Biocon's trastuzumab is the first FDA-approved biosimilar trastuzumab and the first biosimilar from Biocon's portfolio to be approved in the U.S.

It is only the second oncology biosimilar approved by US FDA.

In addition, the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for Biocon's proposed biosimilar trastuzumab for review.

Abdi Ibrahim Remede Pharma (AIRP) as Biocon's commercialization partner in Algeria launched the first biosimilar of trastuzumab named CANMAb® in 2016.

Under its collaboration with Biocon in Algeria, AIRP also launched the first biosimilar of insulin glargine named BasalogOne® in 2017.

Both these products are making a difference to patients by allowing them access to affordable biologics for diseases like diabetes and cancer.

The global biologics drug market stands at an estimated US\$ 231 billion.

Under collaboration with Biocon, AIRP's biosimilars operate in the biologics market which is valued over one third of the US\$1 billion total Algeria pharma market.

The introduction and strong adoption of biosimilars in Algeria is expected to facilitate access to safe and effective biological products as well as create substantial savings for the government.

In Europe, with over a decade of experience, biosimilar adoption rates have significantly increased.

It is estimated that regulations on biosimilars adapted to the country's health and economic interests will enable Algeria to reduce its import bill by at least US\$ 350 million in 2018 alone.